See how your reported results read as versioned evidence records β linked to experiments and limitations.Know what the science actually supports before you trust the answer.
Press Enter β΅ to review claims
Explore by Goal
"The cosmos is within us. We are made of star-stuff. We are a way for the universe to know itself."
- Carl Sagan
Quick Explanation
Copied
Magdalena Rogut β scientific footprint (based on provided works)
The provided publication set shows work spanning diagnostic fetal imaging markers, endometriosis biomarker research, molecular oncology pathway modulation (HSP90/NF-ΞΊB), and clinical case-based surgical managementβwith at least two items in peer-reviewed journals accessible via DOI.
Evidence base used: the works explicitly listed in the prompt (with DOIs available for 4 items). No external assumptions beyond the provided bibliographic/DOI information are added.
1) What the provided paper set covers (by topic)
Fetal diagnostics / imaging marker: inter-ventricular septal thickness as a diagnostic marker of fetal macrosomia ().
Biomarkers for endometriosis: NGF expression in endometrium as a potential endometriosis biomarker ().
Molecular mechanism (cancer signaling): HSP90 inhibition by 17-aminogeldanamycin suppresses constitutive NF-ΞΊB activity in patient-derived melanoma cell lines ().
Clinical case-based evidence (respiratory surgery): curative lobectomy for a pulmonary arteriovenous fistula case ().
2) Visual evidence map (timeline of provided DOI-covered works)
Evidence note: this timeline is strictly based on years in the provided DOI entries; it does not represent the authorβs entire oeuvre.
The set includes both human-facing diagnostic/biomarker work (prenatal imaging marker for fetal macrosomia; NGF expression as an endometriosis biomarker candidate) and cellular mechanistic work (HSP90 inhibition impacting NF-ΞΊB activity in patient-derived melanoma cell lines) (; ; ).
There is also evidence of clinical communication/publishing via a case report (), but case reports have inherently limited generalizability compared with controlled studies.
3.2 Evidence strength: knowns vs uncertainties
(A) Diagnostic/biomarker claims
The fetal macrosomia marker work is positioned as addressing inadequate performance of commonly used prenatal predictors, implying the proposed marker may improve early detection, but the provided prompt does not include the paperβs sensitivity/specificity, validation strategy, or calibration detailsβso those quantitative strengths/weaknesses are unknown here ().
The NGF endometrium biomarker study explicitly states a βsingle tertiary care centreβ context in its title, which raises uncertainty about external validity and population-level generalization (selection effects, center-specific assays, and case mix) ().
(B) Mechanistic/cell-line claims
The melanoma mechanistic paper targets a defined signaling axis: HSP90 inhibition via 17-aminogeldanamycin reduces constitutive NF-ΞΊB activity in patient-derived melanoma cell lines. That is a more experimentally direct claim than biomarker association studies, but the prompt does not include effect sizes, controls (e.g., pathway specificity), dose-response breadth, or whether results translate beyond cell linesβso translation uncertainty remains ().
(C) Clinical case-based claims
The pulmonary AV fistula item is a case report, so its main contribution is clinical illustration rather than establishing causal efficacy across a population ().
4) Reproducibility & bias checkpoints (what to verify in the full texts)
Biomarker transferability: check whether assays, specimen handling, and scoring thresholds were standardized and whether external cohorts/independent replication were used (particularly relevant to the single-center NGF endometrium study context) ().
Diagnostic performance: for the fetal macrosomia marker, verify the validation design (training/test split, calibration), and ensure the marker is not simply an association that overfits within a cohort ().
Mechanistic specificity: for the NF-ΞΊB modulation work, check whether effects are specific to the intended pathway (e.g., using pathway controls or orthogonal readouts), and whether results are consistent across patient-derived lines ().
Case-report limits: treat the lobectomy case as hypothesis-generating; verify details like follow-up duration and outcome definitions, but do not interpret it as population-level evidence ().
5) Useful next-step queries on BGPT
Confidence: Medium for topic identification (titles/DOIs provided); low-to-medium for claims about methodological quality because the full-text details (sample sizes, blinding, controls, effect sizes) are not included in the prompt.
Feedback:
Updated: April 15, 2026
BGPT Author Review
Scientific Quality
60%
The authorβs provided record suggests ability to publish across multiple biomedical subdomains (diagnostic/biomarker framing, mechanistic cell-line signaling, and clinical case writing). However, the prompt does not include full methodological details needed to judge rigor (sample size/controls/validation/replication). The molecular paperβs patient-derived framing is a positive signal, while biomarker and diagnostic claims likely require stronger external validation. Overall: moderate scientific quality with insufficient evidence here to confirm world-class rigor across all domains.
Communication Quality
60%
Communication quality cannot be directly assessed without abstracts/full texts. Based on bibliographic titles alone, the claims appear topic-relevant and structured, but title-level information is not enough to evaluate clarity, logic, limitations disclosure, or statistical transparency.
Author Novelty
40%
Novelty is uncertain from titles/DOIs alone. The research appears to target specific biomarkers/markers/pathway modulation, which may be incremental relative to established domains, but novelty cannot be validated without reviewing study design and differentiators versus prior work.
Scientific Rigor
50%
Rigor cannot be scored precisely without full-text methods. Biomarker/diagnostic studies typically require careful validation and calibration; a single-center context suggests potential generalizability limits. The mechanistic cell-line study could be more rigorous, but effect sizes/controls are not provided here, so overall rigor is estimated as moderate.
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
Septal thickness alone is sufficient as a stand-alone predictor of macrosomia with robust generalization across settingsβunlikely because diagnostic markers typically need calibration, external validation, and integration with existing predictors.
NGF expression in endometrium universally and specifically distinguishes endometriosis regardless of center/assay conditionsβunlikely given biological heterogeneity and single-center design limitations indicated by the title.
Science Art
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Explore by Goal
Quick Explanation
Long Explanation
Ask a Follow-Up
Key Insight
Hypothesis Graveyard
Discussion